[1] |
Lei L, Zheng RS, Peng K, et al. Incidence and mortality of oral and oropharyngeal cancer in China, 2015[J]. Chin J Cancer Res, 2020, 32(1): 1-9. DOI: 10.21147/j.issn.1000-9604.2020.01.01.
doi: 10.21147/j.issn.1000-9604.2020.01.01
|
[2] |
Thompson-Harvey A, Yetukuri M, Hansen AR, et al. Rising incidence of late-stage head and neck cancer in the United States[J]. Cancer, 2020, 126(5): 1090-1101. DOI: 10.1002/cncr.32583.
doi: 10.1002/cncr.32583
pmid: 31722124
|
[3] |
Ducatman BS. The role of human papillomavirus in oropharyngeal squamous cell carcinoma[J]. Arch Pathol Lab Med, 2018, 142(6): 715-718. DOI: 10.5858/arpa.2018-0083-RA.
doi: 10.5858/arpa.2018-0083-RA
pmid: 29848036
|
[4] |
Hong A, Lee CS, Jones D, et al. Rising prevalence of human papillomavirus-related oropharyngeal cancer in Australia over the last 2 decades[J]. Head Neck, 2016, 38(5): 743-750. DOI: 10.1002/hed.23942.
doi: 10.1002/hed.23942
|
[5] |
Mehanna H, Franklin N, Compton N, et al. Geographic variation in human papillomavirus-related oropharyngeal cancer: data from 4 multinational randomized trials[J]. Head Neck, 2016, 38(Suppl 1): E1863-E1869. DOI: 10.1002/hed.24336.
doi: 10.1002/hed.24336
|
[6] |
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)头颈部肿瘤诊疗指南: 2020[M]. 北京: 人民卫生出版社, 2020: 24-29.
|
[7] |
Lassen P, Lacas B, Pignon JP, et al. Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: the MARCH-HPV project[J]. Radiother Oncol, 2018, 126(1): 107-115. DOI: 10.1016/j.radonc.2017.10.018.
doi: 10.1016/j.radonc.2017.10.018
|
[8] |
Dogan S, Xu B, Middha S, et al. Identification of prognostic molecular biomarkers in 157 HPV-positive and HPV-negative squamous cell carcinomas of the oropharynx[J]. Int J Cancer, 2019, 145(11): 3152-3162. DOI: 10.1002/ijc.32412.
doi: 10.1002/ijc.32412
|
[9] |
Lacas B, Carmel A, Landais C, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group[J]. Radiother Oncol, 2021, 156: 281-293. DOI: 10.1016/j.radonc.2021.01.013.
doi: 10.1016/j.radonc.2021.01.013
|
[10] |
Rosenthal DI, Harari PM, Giralt J, et al. Association of human papillomavirus and p16 status with outcomes in the IMCL-9815 phase Ⅲ registration trial for patients with locoregionally advanced oropharyngeal squamous cell carcinoma of the head and neck treated with radiotherapy with or without cetuximab[J]. J Clin Oncol, 2016, 34(12): 1300-1308. DOI: 10.1200/JCO.2015.62.5970.
doi: 10.1200/JCO.2015.62.5970
pmid: 26712222
|
[11] |
Bonner JA, Giralt J, Harari PM, et al. Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: assessment from a phase 3 registration trial[J]. Eur J Cancer, 2016, 64: 1-11. DOI: 10.1016/j.ejca.2016.05.008.
doi: 10.1016/j.ejca.2016.05.008
pmid: 27323346
|
[12] |
Gillison ML, Trotti AM, Harris J, et al. Radiotherapy plus cetu-ximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial[J]. Lancet, 2019, 393(10166): 40-50. DOI: 10.1016/S0140-6736(18)32779-X.
doi: S0140-6736(18)32779-X
pmid: 30449625
|
[13] |
Mehanna H, Robinson M, Hartley A, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial[J]. Lancet, 2019, 393(10166): 51-60. DOI: 10.1016/S0140-6736(18)32752-1.
doi: S0140-6736(18)32752-1
pmid: 30449623
|
[14] |
Suton P, Skelin M, Rakusic Z, et al. Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE[J]. Eur Arch Otorhinolaryngol, 2019, 276(5): 1275-1281. DOI: 10.1007/s00405-019-05387-8.
doi: 10.1007/s00405-019-05387-8
|
[15] |
Chera BS, Amdur RJ, Tepper JE, et al. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma[J]. Cancer, 2018, 124(11): 2347-2354. DOI: 10.1002/cncr.31338.
doi: 10.1002/cncr.31338
|
[16] |
Lim SH, Lee SJ, Ahn MJ, et al. Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy: implication for subgroup selection for induction chemotherapy[J]. Jpn J Clin Oncol, 2016, 46(1): 40-45. DOI: 10.1093/jjco/hyv163.
doi: 10.1093/jjco/hyv163
|
[17] |
Pearlstein KA, Wang K, Amdur RJ, et al. Quality of life for patients with favorable-risk HPV-associated oropharyngeal cancer after de-intensified chemoradiotherapy[J]. Int J Radiat Oncol Biol Phys, 2019, 103(3): 646-653. DOI: 10.1016/j.ijrobp.2018.10.033.
doi: 10.1016/j.ijrobp.2018.10.033
|
[18] |
Ma DJ, Price KA, Moore EJ, et al. PhaseⅡevaluation of aggressive dose de-escalation for adjuvant chemoradiotherapy in human papillomavirus-associated oropharynx squamous cell carcinoma[J]. J Clin Oncol, 2019, 37(22): 1909-1918. DOI: 10.1200/JCO.19.00463.
doi: 10.1200/JCO.19.00463
|
[19] |
Burr AR, Harari PM, Ko HC, et al. Reducing radiotherapy target volume expansion for patients with HPV-associated oropharyngeal cancer[J]. Oral Oncol, 2019, 92: 52-56. DOI: 10.1016/j.oralon-cology.2019.03.013.
doi: 10.1016/j.oralon-cology.2019.03.013
|
[20] |
Seiwert TY, Foster CC, Blair EA, et al. OPTIMA: a phase Ⅱ dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer[J]. Ann Oncol, 2019, 30(2): 297-302. DOI: 10.1093/annonc/mdy522.
doi: S0923-7534(19)31029-4
pmid: 31987428
|
[21] |
Strohl MP, Wai KC, Ha PK. De-intensification strategies in HPV-related oropharyngeal squamous cell carcinoma-a narrative review[J]. Ann Transl Med, 2020, 8(23): 1601. DOI: 10.21037/atm-20-2984.
doi: 10.21037/atm-20-2984
|
[22] |
Misiukiewicz K, Gupta V, Miles BA, et al. Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: the Quarterback trial[J]. Oral Oncol, 2019, 95: 170-177. DOI: 10.1016/j.oraloncology.2019.06.021.
doi: S1368-8375(19)30210-6
pmid: 31345387
|
[23] |
Hegde JV, Shaverdian N, Daly ME, et al. Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: findings from a phase 2 trial[J]. Cancer, 2018, 124(3): 521-529. DOI: 10.1002/cncr.30954.
doi: 10.1002/cncr.30954
pmid: 29044458
|
[24] |
Marur S, Li S, Cmelak AJ, et al. E1308: phase Ⅱ trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx-ECOG -ACRIN Cancer Research Group[J]. J Clin Oncol, 2017, 35(5): 490-497. DOI: 10.1200/JCO.2016.68.3300.
doi: 10.1200/JCO.2016.68.3300
|